Close menu




March 31st, 2026 | 08:20 CEST

Dividends as Portfolio Anchors: Familiar Names Sanofi and BB Biotech – Hidden Gem RE Royalties

  • royalties
  • dividends
  • Biotech
  • Pharma
  • Sustainability
  • renewableenergy
Photo credits: AI

In a market environment marked by structural upheaval, portfolio stability is increasingly coming into focus. Analysts at JPMorgan emphasize that preserving accumulated gains requires a renewed focus on resilience and diversification. Research by S&P Global also shows that dividends have contributed over 50% to the total return of global equities over the past 25 years. Choosing the right stocks is crucial to securing steady cash flows even during volatile market phases. Pharmaceutical giant Sanofi, investment firm BB Biotech, and the virtually unknown Canadian company RE Royalties offer fundamentally different but extremely promising approaches for investors.

time to read: 3 minutes | Author: Nico Popp
ISIN: SANOFI SA INHABER EO 2 | FR0000120578 , BB BIOTECH NAM. SF 0_20 | CH0038389992 , RE ROYALTIES LTD | CA75527Q1081 | TSXV: RE , OTCQX: RROYF

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Sanofi: Stability Through Operational Transformation

    The French pharmaceutical group Sanofi presents itself as a classic defensive anchor of stability. In fiscal year 2025, revenue rose by 9.9% to EUR 43.6 billion, driven primarily by the continued success of the blockbuster drug Dupixent. The company recently proposed a dividend of EUR 4.12, marking the 31st consecutive increase. This makes it clear: Sanofi stands for absolute reliability. In February of this year, the group announced a strategic leadership change: Belén Garijo, who previously led Merck KGaA, will take over the CEO position from Paul Hudson in the coming weeks to boost research productivity. Analysts at Bank of America subsequently downgraded the stock to "Neutral" due to concerns about a transition phase. Future upside potential stems primarily from the successful integration of acquisitions such as the takeover of Dynavax, while the dividend is optimally secured thanks to strong free cash flow of EUR 8.1 billion.

    BB Biotech: Returns Thanks to Expertise and Innovation

    The Swiss investment firm BB Biotech provides access to a specialized biotech portfolio. The company closed 2025 with a record profit of CHF 578 million. The strict dividend policy provides for an annual payout of 5% of the average December share price, which corresponds to CHF 2.25 per share for 2025. To enhance fundamental stability, management has recently focused the portfolio heavily on clinically mature and market-leading companies such as Ionis Pharmaceuticals and Argenx. Although BB Biotech provided a somewhat more cautious outlook for 2026, a new share buyback program covering up to 10% of the capital provides downside protection. The dividend is directly linked to investment performance but offers an excellent risk-reward profile with significant upside potential driven by upcoming clinical trial data.

    RE Royalties: The Undiscovered Anchor of Stability

    By far the most exciting approach comes from the Canadian company RE Royalties, which, as a pioneer in its sector, has applied the proven royalty model to renewable energy. The company provides capital to developers of solar, wind, or battery storage projects and, in return, receives a percentage share of gross revenue. This specific structure largely shields revenue from inflation-driven cost increases for operators and ensures stable cash flows through long-term power purchase agreements. The diversified portfolio already includes over 100 royalty agreements in North America, South America, and Asia. With a consistent quarterly dividend of CAD 0.01, the stock boasts an expected dividend yield of well over 10%.

    Exciting business model, promising stock.

    Scalability and Excellent Interest Margins Drive Growth

    A key success factor for RE Royalties lies in the asymmetric financing structure and the model's enormous scalability. By providing project developers with non-dilutive capital, they retain their voting rights and equity stakes, which drives demand for this financing instrument in the cleantech sector. At the same time, RE Royalties benefits from an excellent interest margin. While the company refinances itself via green bonds with an interest rate of around 9%, the licensed investments it makes typically target double-digit returns. Just how attractive this business is in practice is demonstrated by a recent letter of intent for a USD 8 million loan for a wind project in the US, which secures the company a 5% royalty on gross revenue over the entire lifetime of the facility. Since RE Royalties does not operate the renewable energy plants itself, the cost structure remains lean, allowing additional licenses to boost profits with a minimal increase in operating expenses. With a well-stocked investment pipeline of over CAD 200 million and a listing in Germany designed to specifically attract European capital, the foundation for the next phase of growth is solid.

    Strategic Review as a Share Price Driver

    In addition to its exceptionally high and operationally robust dividend, RE Royalties is also drawing attention for its share price potential. The company has been awarded the highest "Dark Green Rating" by sustainability analysts at S&P Global and successfully refinanced itself through green bonds. To finally reflect the company's hidden intrinsic value in the capital market, management recently launched a comprehensive strategic review with external financial advisors. The goal of this initiative is to explore lucrative options such as a full sale of the company or strong strategic partnerships. For investors, this creates a rare opportunity: they receive a double-digit dividend yield from a sustainable infrastructure business while simultaneously holding significant leverage toward an imminent revaluation of the stock.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Armin Schulz on March 31st, 2026 | 07:20 CEST

    Europe is caught in an energy trap, but there are also winners: Siemens Energy, A.H.T. Syngas, and RWE in focus

    • cleantech
    • Gas
    • biochar
    • Energy
    • renewableenergy

    The global energy order is crumbling in the face of two wars. While European pipelines were cut off as a result of the Ukraine conflict, the military conflict in the Persian Gulf is now paralyzing the entire oil trade. For local industry, this historic squeeze poses an existential threat, as Germany’s energy policy has failed to build a robust alternative over the years. Yet it is precisely at the epicenter of these upheavals that billion-dollar profit zones are emerging. A look at three companies shows how they are turning the collapse of the old world into profit: Siemens Energy, A.H.T. Syngas, and RWE.

    Read

    Commented by Nico Popp on March 31st, 2026 | 07:05 CEST

    Resilience in Logistics: Daimler Truck and Nel Explore a Hydrogen Future – dynaCERT Bridges the Gap

    • Hydrogen
    • cleantech
    • GreenTech
    • renewableenergy

    The logistics sector faces major challenges that highlight just how dependent it is on fossil fuels. An escalating conflict in the Middle East and the blockade of the Strait of Hormuz have shaken energy markets and led to rising prices for petroleum products and their derivatives. Particularly alarming is the price surge for diesel, the primary fuel for global heavy-duty transport. According to current market data, diesel prices on the London Stock Exchange have jumped by about 27 cents per liter since the end of February 2026. The economic consequences are enormous: simulations by the German Economic Institute show that a sustained oil price of USD 100 per barrel could result in real economic damage of about EUR 40 billion over two years. In this context, hydrogen is no longer seen merely as a tool for greater sustainability but as a prerequisite for resilience in energy matters. In this transformation process, the business models of Daimler Truck, Nel ASA, and dynaCERT complement one another. We analyze the solutions, which range from far-reaching visions for the future of mobility to immediate efficiency gains in heavy-duty engines.

    Read

    Commented by Nico Popp on March 30th, 2026 | 08:30 CEST

    A Paradigm Shift in Oncology: Core Stocks Roche & Galderma and the High-Leverage Opportunity in Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations
    • Cancer

    Medical advances affect us all. Oncology is also undergoing a transformation. As conventional immunotherapies for skin cancer increasingly reach their limits, clinical research is shifting its focus to correcting defective tumor metabolism. The Warburg effect, where cancer cells shift energy production to aerobic glycolysis to fuel uncontrolled growth, offers a promising entry point. This dynamic development landscape is exacerbated by an impending patent cliff, which, according to calculations by the consulting firm PwC, threatens industry revenues of USD 104 billion by 2028, as many patents for active ingredients are expiring. Currently, market researchers at Fortune Business Insights estimate the volume of the global oncology market for 2026 at USD 286.36 billion. While pharmaceutical giant Roche secures its market leadership and the Galderma Group dominates standard dermatological care, biotechnology company Vidac Pharma is targeting the metabolic vulnerability of cancer cells with a completely novel mechanism of action, aiming to effectively shut down the cancer.

    Read